TLX

Telix Pharmaceuticals Ltd

Add to Watchlist

Advanced Chart

16.250

-0.150(-0.910%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

16.480

Open

16.280

VWAP

16.29

Vol

6.03K

Mkt Cap

5.49B

Low

16.000

Amount

98.26K

EV/EBITDA(TTM)

171.03

Total Shares

675.94M

16.93B

EV/OCF(TTM)

393.46

P/S(TTM)

11.08

Telix Pharmaceuticals Limited is an Australia-based is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical devices. It develops a portfolio of clinical and commercial stage products that addresses significant unmet medical needs in oncology and rare diseases. It operates a pipeline of theranostic radiopharmaceutical product candidates with a focus in urologic oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma) and bone marrow conditioning. It operates under four business units: Therapeutics, Precision Medicine (Diagnostics), Lightpoint (Medtech), and Telix Manufacturing Solutions (TMS). Its lead imaging product is gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11 and marketed under the brand name Illuccix). Its other pipelines include TLX591, TLX592, TLX250, TLX250-CDx, TLX101, TLX101-CDx, TLX300, TLX300-CDx, TLX66, and TLX66-CDx.

Valuation Metrics

The current forward P/E ratio for Telix Pharmaceuticals Ltd (TLX.O) is 70.31, compared to its 5-year average forward P/E of 78.48. For a more detailed relative valuation and DCF analysis to assess Telix Pharmaceuticals Ltd 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair

5Y Average PE

78.48

Current PE

70.31

Overvalued PE

91.14

Undervalued PE

65.82

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair

5Y Average EV/EBITDA

48.68

Current EV/EBITDA

43.06

Overvalued EV/EBITDA

57.29

Undervalued EV/EBITDA

40.07

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

7.62

Current PS

6.77

Overvalued PS

8.81

Undervalued PS

6.42

Financials

Annual

Quarterly

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

TLX News & Events

Events Timeline

2025-04-15 (ET)

2025-04-15

18:40:37

Telix's glioma therapy candidate shows 'encouraging' preliminary efficacy data

2025-04-07 (ET)

2025-04-07

06:32:02

Telix names Paul Schaffer as Chief Technology Officer

2025-04-01 (ET)

2025-04-01

15:32:19

Telix doses first patient in ZOLAR trial of TLX300-CDx

News

9.0

04-28Newsfilter

Telix's Illuccix PSMA-PET Imaging Agent Approved in France

9.0

04-28PRnewswire

Telix's Illuccix PSMA-PET Imaging Agent Approved in France

9.5

04-22Newsfilter

Telix Reports US$186M Q1 Revenue, Up 62% YOY

People Also Watch

FAQ

What is Telix Pharmaceuticals Ltd (TLX) stock price today?

The current price of TLX is 16.25 USD — it has decreased -0.91 % in the last trading day.

TLX

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

TLX News & Events

Events Timeline

News

People Also Watch

FAQ

What is Telix Pharmaceuticals Ltd (TLX) stock price today?

What is Telix Pharmaceuticals Ltd (TLX)'s business?

What is the price predicton of TLX Stock?

What is Telix Pharmaceuticals Ltd (TLX)'s revenue for the last quarter?

What is Telix Pharmaceuticals Ltd (TLX)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Telix Pharmaceuticals Ltd (TLX)'s fundamentals?

How many employees does Telix Pharmaceuticals Ltd (TLX). have?

What is Telix Pharmaceuticals Ltd (TLX) market cap?